Clinical Trials Logo

Eltrombopag clinical trials

View clinical trials related to Eltrombopag.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04600960 Recruiting - Clinical trials for Chemotherapy-induced Thrombocytopenia

Eltrombopag for Chemotherapy-induced Thrombocytopenia

Start date: December 31, 2020
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of eltrombopag to treat chemotherapy-induced thrombocytopenia in solid tumors

NCT ID: NCT03701217 Recruiting - Clinical trials for Acute Myeloid Leukemia

Eltrombopag Used in Thrombocytopenia After Comsolidation Therapy in AML

Start date: September 10, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

Eltrombopag has been used in the treatment of immune thrombocytopenia (ITP), and significantly increased platelet count and decreased fatal hemorrage. As it's known that all patients with acute leukemia will experience bone marrow suppression and thrombocytopenia after chemotherapy. Some patients even died of fatal bleeding during this period for lacking of platelet transfusion or platelet transfusion refractoriness. So a lot needs to be done to shortern thrombocytopenia time or reduce fatal hemorrage incidence after chemotherapy in acute leukemia patients. In this prospective randomized controlled study, the effect and safety of eltrombopag in the treatment of thrombocytopenia after consolidation therapy in acute myeloid leukemia (AML) is evaluated.